No matter what happens to the economy, people aren’t going to stop taking their prescription medications. As a result, the author of today’s article suggests that companies in the biotech sector are likely to demonstrate immunity to any economic downturn. Moreover, a number of biotechs are actively involved in the fight against the novel coronavirus, working aggressively on the development of potential vaccines and therapeutics. As such, the author advises that “opportunity knocks for those brave souls willing to buy biotechs in this volatile and exceedingly moody market” – and he highlights five biotechs that are “too cheap to ignore right now”. CLICK HERE.